Philadelphia, September 25, 2025 – Verismo Therapeutics, a clinical-stage biotechnology company specializing in KIR-CAR T cell therapies, has announced a collaboration with Miltenyi Biotec to support its Phase 1 STAR-101 clinical trial. The partnership enables the supply of commercial-ready lentiviral vectors for manufacturing Verismo’s lead candidate, SynKIR™-110, targeting mesothelin in solid tumors. This milestone marks the first production of clinical cell product using Miltenyi’s lentiviral platform, laying the foundation for Phase 2 readiness and future commercial use.
Science Significance
SynKIR™-110 utilizes Verismo’s proprietary multi-chain KIR-CAR platform, combining NK cell-derived KIR and DAP12 signaling to enhance T cell functional persistence and efficacy. Preclinical studies demonstrate that KIR-CAR T cells resist tumor immunosuppression, maintain prolonged activity, and achieve superior tumor elimination compared with conventional CAR T therapies. Miltenyi’s lentiviral vectors ensure reproducible transduction and high-quality production, essential for consistent clinical outcomes.
Regulatory Significance
The collaboration addresses regulatory expectations by providing a GMP-compliant and scalable supply chain, a critical step for FDA filings and global approvals. The use of validated viral vectors supports the STAR-101 trial’s design, aligning manufacturing processes with regulatory standards for both clinical and potential commercial applications.
Business Significance
Advertisement
This partnership strengthens Verismo’s strategic positioning in next-generation CAR T therapy, enhancing manufacturing continuity and trial scalability. Miltenyi Biotec’s Bioindustry division provides end-to-end vector solutions, from process development to GMP production, enabling Verismo to accelerate its STAR-101 clinical program. The collaboration signals investor confidence and potential for future partnerships, bolstering Verismo’s commercial strategy.
Patients’ Significance
Patients with advanced solid tumors face limited treatment options, particularly for CAR-resistant cancers. SynKIR™-110’s innovative KIR-CAR design aims to improve T cell persistence and reduce exhaustion, offering sustained anti-tumor activity and potentially improved clinical outcomes. By targeting mesothelin, SynKIR™-110 addresses a high unmet medical need, potentially providing a first-in-class therapy for difficult-to-treat tumors.
Policy Significance
The collaboration highlights the value of public-private partnerships and specialized CDMOs in advancing next-generation therapies. By ensuring GMP-compliant production, Verismo and Miltenyi set a precedent for regulatory expectations in autologous and engineered cell therapies. This model supports broader policy goals to accelerate translation of cutting-edge biotherapeutics from research to clinical implementation.
Transaction Highlights
Verismo Therapeutics has partnered with Miltenyi Biotec’s Bioindustry division to supply commercial-ready lentiviral vectors for the STAR-101 Phase 1 clinical trial, enabling the successful manufacture of its first clinical cell product, SynKIR™-110. This collaboration ensures a reliable supply chain and establishes the foundation for Phase 2 expansion and potential commercial use. Miltenyi Bioindustry provides expertise across the full spectrum of vector production, from design and research to GMP manufacturing, supporting consistent and high-quality cell products. Both companies maintain oversight of manufacturing and quality control, reinforcing Verismo’s commitment to clinical readiness, scalability, and future commercialization.
Source: Verismo Therapeutics Press Release
